Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma based on standard diagnosis criteria: plasmacytomas on tissue biopsy; bone marrow plasmacytosis; monoclonal immunoglobulin spike on serum electrophoresis; lytic bone lesions.~* Must have relapsed or relapsed/refractory disease~* 18 years of age or older~* All baseline studies must be performed within 21 days of enrollment.~* ECOG performance status of 0 to 2~Exclusion Criteria:~* Renal insufficiency (serum creatinine levels \> 2mg/dL)~* Concomitant therapy medications that include corticosteroids~* Peripheral neuropathy of Grade 3 or greater or painful Grade 2~* Evidence of mucosal or internal bleeding and/or platelet refractory~* ANC \< 1000 cells/mm3~* Hemoglobin \< 8.0 g/dL~* AST (SGOT and ALT) \> 2 x ULN~* Intolerance to bortezomib or CC-5013 in the past or significant allergy to either compound, boron or mannitol~* Known hypersensitivity to thalidomide or the development of erythema nodosum~* Active infection or serious co-morbid medical condition~* Pregnant or breast-feeding women~* Prior malignancy with the last three years except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, on in-situ prostate cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-5013 in combination with bortezomib (Type: EXPERIMENTAL): Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).